Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
CALGARY, Alberta, Oct. 16, 2017 -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces its participation in the upcoming BIO Investor Forum in San Francisco, CA. Mr. Donald J. McCaffrey, President and Chief Executive Officer, will provide a corporate update and overview of recent activities at the conference.
Presentation & Webcast Details:
Date: Tuesday, October 17th
Time: 11:15 am PT
Duration: ~15 minutes
Location: Elizabethan D Room at the Westin St. Francis
Webcast Link: Click hear to launch the webcast viewer
The presentation will be available on the Company’s website immediately prior to the start of the event. Click on this LINK to go directly to the appropriate page on the Company’s website. An archived replay of the webcast will also be available on the Company website by clicking on this LINK.
About Zenith
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”).
For further information, please contact:
Clayton Paradis
Zenith Capital Corp.
Phone: 587-390-7865
Email: [email protected]
Website: www.zenithepigenetics.com
